Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 33
Phase 42

Trial Status

Completed9
Terminated1

Role Distribution

Principal Investigator10
PI Rate100%

Activity Timeline

Clinical Trials (10)

NCT00258713Phase 3Completed
A 36-Week Extension to Protocol ISA04-03
Psoriasis
Principalinvestigator
NCT00629772Phase 3Completed
Safety and Efficacy of Infliximab in Palmoplantar Psoriasis
Palmoplantar Psoriasis
Principalinvestigator
NCT00940862Phase 4Completed
Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis
Coronary AtherosclerosisPsoriasisVascular Inflammation
Principalinvestigator
NCT01722214Phase 4Completed
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
Coronary AtherosclerosisPsoriasisVascular Inflammation
Principalinvestigator
NCT02078297Completed
IL-17 Role in Variants of Psoriasis
Elbow PsoriasisLower Leg PsoriasisNon-pustular Palmo-plantar Psoriasis+2 more
Principalinvestigator
NCT02270411Completed
Inflammatory Cells From Various Pathologies
Acne RosaceaAcne VulgarisAtopic Dermatitis
Principalinvestigator
NCT02305953Completed
Cytokines and Vascular Inflammation in Psoriasis
Coronary AtherosclerosisPsoriasisVascular Inflammation
Principalinvestigator

Research Network

Collaboration Network

14 collaborators·24 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jean-Claude Tardif, MD, FRCPC

Montreal Heart Institute

Moderately Similar
1 trials

Shared therapeutic areas:

Coronary ArteriosclerosisPsoriasisVascular Inflammation

Worked with same sponsors:

AbbottInnovaderm Research Inc.+1 more
Collaborated on 1 trial
Similarity Score34%

Jean-Claude Tardif, MD

Montreal Heart Institute

Moderately Similar
13 trials

Shared therapeutic areas:

Coronary ArteriosclerosisPsoriasisVascular Inflammation

Worked with same sponsors:

AbbottInnovaderm Research Inc.+1 more
Collaborated on 1 trial
Similarity Score34%

Richard Langley, MD, FRCPC

Eastern Canada Cutaneous Research Associates Ltd.

Related
2 trials

Shared therapeutic areas:

Psoriasis

Worked with same sponsors:

Aurinia Pharmaceuticals Inc.
Collaborated on 2 trials
Similarity Score18%

Kim Papp, MD, PhD

Probity Medical Research

Related
2 trials

Shared therapeutic areas:

Psoriasis

Worked with same sponsors:

Aurinia Pharmaceuticals Inc.
Collaborated on 2 trials
Similarity Score18%

Gilles Lauzon, PhD MD FRCPC

University of Alberta

Related
1 trials

Shared therapeutic areas:

Psoriasis

Worked with same sponsors:

Aurinia Pharmaceuticals Inc.
Collaborated on 1 trial
Similarity Score14%

Neil Shear, MD

Ventana Clinical Research Organization

Related
1 trials

Shared therapeutic areas:

Psoriasis

Worked with same sponsors:

Aurinia Pharmaceuticals Inc.
Collaborated on 1 trial
Similarity Score14%

Neil Shear, MD

Ventana Clinical Research Corporation

Related
1 trials

Shared therapeutic areas:

Psoriasis

Worked with same sponsors:

Aurinia Pharmaceuticals Inc.
Collaborated on 1 trial
Similarity Score14%

Gilles Lauzon, PhD MD FRCPC

Western Canada Dermatology Institute

Related
1 trials

Shared therapeutic areas:

Psoriasis

Worked with same sponsors:

Aurinia Pharmaceuticals Inc.
Collaborated on 1 trial
Similarity Score14%

Ronald W Gottschalk, MD

Galderma R&D

Related
19 trials

Shared therapeutic areas:

RosaceaAcne VulgarisPsoriasis+1 more
Similarity Score10%

Sabine Hazan, MD

ProgenaBiome

Related
41 trials

Shared therapeutic areas:

PsoriasisRosaceaAcne Vulgaris
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (10)

Showing 10 of 10 trials

NCT00244842Phase 3PrincipalInvestigator

Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis

Psoriasis
Completed
NCT00258713Phase 3PrincipalInvestigator

A 36-Week Extension to Protocol ISA04-03

Psoriasis
Completed
NCT00624676Not ApplicablePrincipalInvestigator

Efficacy and Tolerance of a Derivative of Salicylic Acid and 5% Benzoyl Peroxide in Facial Acne Vulgaris

Acne Vulgaris
Completed
NCT00629772Phase 3PrincipalInvestigator

Safety and Efficacy of Infliximab in Palmoplantar Psoriasis

Palmoplantar Psoriasis
Completed
NCT00931411Not ApplicablePrincipalInvestigator

Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis

Atopic Dermatitis
Terminated
NCT00940862Phase 4PrincipalInvestigator

Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

Coronary AtherosclerosisPsoriasisVascular Inflammation
Completed
NCT01722214Phase 4PrincipalInvestigator

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

Coronary AtherosclerosisPsoriasisVascular Inflammation
Completed
NCT02078297PrincipalInvestigator

IL-17 Role in Variants of Psoriasis

Elbow PsoriasisLower Leg PsoriasisNon-pustular Palmo-plantar Psoriasis+2 more
Completed
NCT02270411PrincipalInvestigator

Inflammatory Cells From Various Pathologies

Acne RosaceaAcne VulgarisAtopic Dermatitis
Completed
NCT02305953PrincipalInvestigator

Cytokines and Vascular Inflammation in Psoriasis

Coronary AtherosclerosisPsoriasisVascular Inflammation
Completed

All 10 trials loaded